SEK 0.97
(-1.62%)
Year | Eps | Eps Growth |
---|---|---|
2023 | -3.48 SEK | 63.14% |
2022 | -9.44 SEK | -14.29% |
2021 | -8.26 SEK | 5.06% |
2020 | -8.70 SEK | -11.97% |
2019 | -7.77 SEK | 11.9% |
2018 | -8.82 SEK | -202.05% |
2017 | -2.92 SEK | -13.18% |
2016 | -2.58 SEK | 0.0% |
Year | Eps | Eps Growth |
---|---|---|
2024 Q1 | -0.48 SEK | -4.35% |
2024 Q2 | -0.56 SEK | -16.67% |
2023 Q2 | -2.24 SEK | -8.21% |
2023 FY | - SEK | 63.14% |
2023 Q1 | -2.07 SEK | 11.54% |
2023 Q4 | -0.46 SEK | 17.86% |
2023 Q3 | -0.56 SEK | 75.0% |
2022 FY | - SEK | -14.29% |
2022 Q4 | -2.34 SEK | -14.15% |
2022 Q3 | -2.05 SEK | 20.23% |
2022 Q2 | -2.57 SEK | -4.05% |
2022 Q1 | -2.47 SEK | -36.46% |
2021 Q2 | -2.47 SEK | -14.35% |
2021 FY | - SEK | 5.06% |
2021 Q3 | -1.68 SEK | 31.98% |
2021 Q4 | -1.81 SEK | -7.74% |
2021 Q1 | -2.16 SEK | -2.86% |
2020 FY | - SEK | -11.97% |
2020 Q4 | -2.10 SEK | -16.67% |
2020 Q2 | -2.37 SEK | 2.47% |
2020 Q3 | -1.80 SEK | 24.05% |
2020 Q1 | -2.43 SEK | 10.33% |
2019 Q2 | -1.92 SEK | -20.75% |
2019 FY | - SEK | 11.9% |
2019 Q4 | -2.71 SEK | -77.12% |
2019 Q3 | -1.53 SEK | 20.31% |
2019 Q1 | -1.59 SEK | 7.56% |
2018 Q2 | -1.53 SEK | -48.54% |
2018 Q3 | -1.26 SEK | 17.65% |
2018 Q1 | -1.03 SEK | -9.57% |
2018 Q4 | -1.72 SEK | -36.51% |
2018 FY | - SEK | -202.05% |
2017 FY | - SEK | -13.18% |
2017 Q2 | -1.65 SEK | -8.55% |
2017 Q3 | -0.69 SEK | 58.18% |
2017 Q4 | -0.94 SEK | -36.23% |
2017 Q1 | -1.52 SEK | 0.0% |
2016 FY | - SEK | 0.0% |
Name | Eps | Eps Difference |
---|---|---|
AddLife AB (publ) | 1.56 SEK | 323.077% |
Biotage AB (publ) | 3.33 SEK | 204.505% |
Bonesupport Holding AB (publ) | 3.77 SEK | 192.308% |
Doxa AB (publ) | 0.60 SEK | 680.0% |
Elekta AB (publ) | 3.41 SEK | 202.053% |
iZafe Group AB (publ) | -0.14 SEK | -2385.714% |
Ortivus AB (publ) | -0.41 SEK | -748.78% |
Ortivus AB (publ) | -0.41 SEK | -748.78% |
S2Medical AB (publ) | -0.14 SEK | -2385.714% |
Synsam AB (publ) | 2.09 SEK | 266.507% |